Galectin Therapeutics Inc

PHPN

Company Profile

  • Business description

    Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

  • Contact

    4960 Peachtree Industrial Boulevard
    Suite 240
    NorcrossGA30071
    USA

    T: +1 678 620-3186

    E: [email protected]

    https://www.galectintherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    15

Stocks News & Analysis

stocks

Plunge in ASX share unwarranted

Weak result distracts from improving trading and cost outlook.
stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,057.6048.70-0.53%
CAC 407,857.9814.04-0.18%
DAX 4023,589.1422.19-0.09%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,202.9220.40-0.22%
HKSE26,518.65359.531.37%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,630.31136.650.30%
NZX 50 Index13,181.3144.770.34%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,764.5050.50-0.57%
SSE Composite Index3,853.6431.810.83%

Market Movers